# A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

> **NCT05730218** · PHASE2 · COMPLETED · sponsor: **ONL Therapeutics** · enrollment: 136 (actual)

## Conditions studied

- Rhegmatogenous Retinal Detachment - Macula Off

## Interventions

- **DRUG:** ONL1204 Ophthalmic Solution
- **DRUG:** Sham treatment

## Key facts

- **NCT ID:** NCT05730218
- **Lead sponsor:** ONL Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-04
- **Primary completion:** 2024-02-21
- **Final completion:** 2024-02-21
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05730218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05730218, "A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05730218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*